BIOMARIN PHARMACEUTICAL INC
BIOMARIN PHARMACEUTICAL INC. - MATERIAL CONTRACT
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>2
<FILENAME>graceredact3.html
<DESCRIPTION>BIOMARIN PHARMACEUTICAL INC. - MATERIAL CONTRACT
<TEXT>

<HTML>
<HEAD>
<TITLE>
</TITLE>
</head>
<BODY>
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>LICENSE
AGREEMENT</FONT></H1>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This License Agreement is made and entered into by and between BioMarin Pharmaceutical Inc., having its
principal place of business at 371 Bel Marin Keys Boulevard, Suite 210, Novato, CA 94949 ("BioMarin") and W. R.
Grace &amp; Co., having its principal place of business at 7500 Grace Drive, Columbia, MD 21046 ("Grace").  Each of
BioMarin and Grace may be referred to herein individually as a "Party" and collectively as the "Parties."</FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, Grace owns certain Patent Rights and Related Technology, as defined below; and</FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS,
BioMarin was previously granted an Option to acquire an exclusive worldwide
license thereunder, in the Option Agreement dated May 1, 1998 between the
Parties (&#147;Option Agreement&#148;); and </FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, BioMarin has now exercised its Option for such exclusive license;</FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW, THEREFORE, in consideration of the premises and mutual covenants contained herein, BioMarin and Grace
hereby agree as follows:</FONT></P>


<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>ARTICLE I -
DEFINITIONS</FONT></H1>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.01&nbsp;&nbsp;
&#147;Affiliate&#148; means any corporation or other business entity which
directly or indirectly controls, is controlled by, or is under common control
with one of the Parties hereto. &#147;Controls&#148; (including &#147;controlled
by&#148; and &#147;under common control with&#148;) means the possession, direct
or indirect, of the power to direct or cause the direction of the management and
policies of a corporation or other business entity, whether through the
ownership of voting securities, by contract or otherwise. </FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.02&nbsp;&nbsp;"Agreement" means this License Agreement.</FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.03
&nbsp;&nbsp;&#147;ANS&#148; or &#147;Annual Net Sales&#148; shall mean the total of the Net
Sales Prices for all Licensed Products sold by BioMarin, BioMarin sublicensees
and BioMarin distributors to third parties during a Contract Year. </FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.04&nbsp;&nbsp;"BioMarin" shall mean BioMarin Pharmaceutical Inc., having a place of business at 371 Bel Marin
Keys Boulevard, Suite 210, Novato, CA 94949.</FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.05
&nbsp;&nbsp;&#147;Contract Year&#148; shall mean each successive twelve (12) month period
during the term of this Agreement beginning on the Effective Date or
anniversaries thereof. </FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.06
&nbsp;&nbsp;&#147;Earned Royalty&#148; shall mean the royalties based on sales or transfers
of Licensed Product to third parties, as specified in Paragraph 3.03. </FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.07&nbsp;&nbsp;"Effective Date" shall mean January 1, 2001.</FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.08
&nbsp;&nbsp;&#147;First Commercial Sale&#148; shall mean the first sale for commercial
purposes by BioMarin or a BioMarin sublicensee or a BioMarin distributor of a
Licensed Product following approval by the Federal Food &amp; Drug
Administration (if in the United States) or other appropriate regulatory agency
(if outside the United States). For the purpose of this definition,
&#147;commercial purposes&#148; is not intended to mean or include sales or
transfers made solely for research purposes or for clinical trial purposes (even
if token remuneration is received) or for inventory purposes (consignment inventory or
inventory sold to a distributor at below market prices but not yet sold to a
third party). </FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.09&nbsp;&nbsp;"Grace" shall mean W. R. Grace &amp; Co., having its principal place of business at 7500 Grace Drive,
Columbia, MD 21044, and Affiliates thereof.</FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.10&nbsp;&nbsp;"License Maintenance Fee" shall mean the annual fee payable by BioMarin to Grace pursuant to
Paragraph 3.01 for each Contract Year up to and including the Contract Year in which the First Commercial Sale is
made.</FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.11
&nbsp;&nbsp;&#147;Licensed Product&#148; shall mean any product whose manufacture, use,
offer for sale or sale would infringe a Valid Claim in the country for which
such product is manufactured, used, offered for sale or sold. </FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.12
&nbsp;&nbsp;&#147;Minimum Annual Royalty&#148; shall mean the minimum royalty payable in
each Contract Year following the First Commercial Sale of Licensed Product, as
specified by Paragraph 3.02, in order for BioMarin to maintain its license in
the event that Earned Royalties for that Contract Year are zero or less than the
minimum. </FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.13
&nbsp;&nbsp;&#147;Net Sales Price&#148; means the sales price for Licensed Product sold by
BioMarin or a BioMarin sublicensee or a BioMarin distributor to third parties,
less (i) sales, excise, or use taxes separately stated on the face of the
invoice, (ii) transportation or insurance charges separately stated and itemized
on the face of the invoice, (iii) customs duties, and (iv) all return, trade and
discount allowances or credits actually given. </FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.14&nbsp;&nbsp;"Patent Rights" shall mean all subject matter claimed in the following:</FONT></P>
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)
&nbsp;&nbsp;United States Patent Numbers 5,145,681 and 5,505,943 and any continuations,
continuations-in-part, divisions and substitutions of any such patent and all
renewals, reissues and extensions of any such patent; and </FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)
&nbsp;&nbsp;Any foreign patents and/or applications that are counterparts of a patent
described in subparagraph 1.14(a), including any patent or application filed by
or on behalf of Grace that claims subject matter claimed in, or takes priority
from, a patent described in Subparagraph 1.14(a). Such foreign patents and/or
applications as of the Effective Date are listed in Appendix A, attached hereto
and made a part of this Agreement. </FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.15
&nbsp;&nbsp;&#147;Related Technology&#148; shall mean any biological materials, and any
research and development information, inventions, know-how, and all
pre-clinical, clinical and other technical data, in each case, that were owned
by Grace, or possessed by Grace with the right to provide to others, as of May
1, 1998, the effective date of the Option Agreement, which in each case relate
to the practice of the Patent Rights. The Related Technology has already been
provided to BioMarin. </FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.16
&nbsp;&nbsp;&#147;Valid Claim&#148; shall mean a claim of an issued patent included within
the Patent Rights, which has not been held unenforceable or invalid by a court
or other governmental agency of competent jurisdiction, and which has not been
admitted to be invalid or unenforceable through reissue, disclaimer or
otherwise. </FONT></P>

<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>ARTICLE II -
LICENSE GRANT</FONT></H1>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.01
&nbsp;&nbsp;Subject to payment of the fees and royalties specified in Article III below,
Grace hereby grants to BioMarin an exclusive, worldwide, royalty-bearing license
under the Patent Rights and Related Technology, to make, use, offer to sell and
sell Licensed Products, to practice any process, method or procedure of the
Patent Rights and Related Technology and to otherwise exploit the Patent Rights
and Related Technology. </FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.02
&nbsp;&nbsp;BioMarin&#146;s license rights include the right to grant sublicenses to
practice under the Patent Rights and Related Technology within the scope of
BioMarin&#146;s license rights, subject to the following: </FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;Any sublicense granted by BioMarin shall contain the following provisions:</FONT></P>
<p><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i.&nbsp;&nbsp;confidentiality obligations as in Article IV;</FONT></P>
<p><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii.&nbsp;&nbsp;record and audit provisions as in Paragraph 2.04;</FONT></P>
<p><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iii.&nbsp;&nbsp;an agreement by the sublicensee to cooperate with Grace and BioMarin in
                           any actions pursuant to Paragraph 7.02 to prevent or eliminate infringement of any Patent Rights;</FONT></P>
<p><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iv.&nbsp;&nbsp;compliance provisions as in Paragraphs 5.04, 5.05, and 10.04;</FONT></P>
<p><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;v.&nbsp;&nbsp;termination provisions as in Article VIII; and</FONT></P>
<p><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;vi.&nbsp;&nbsp;acknowledgment by the sublicensee that it is not acquiring any right,
title or interest in or to the Patent Rights and Related Technology or any portion
thereof, except as expressly permitted by Grace&#146;s license to BioMarin in
this Agreement, and that upon termination of this Agreement all rights thereby
acquired by each sublicensee shall immediately and automatically extinguish.</FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)
&nbsp;&nbsp;Practice of the Patent Rights and Related Technology by such BioMarin
sublicensee(s) shall be subject to Earned Royalties as if practiced by BioMarin,
and BioMarin shall pay Earned Royalties to Grace on behalf of its sublicensee(s)
pursuant to Paragraphs 3.03 through 3.06. </FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
(c)&nbsp;&nbsp;BioMarin shall promptly notify Grace of each sublicense granted.</FONT></P>
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
(d)&nbsp;&nbsp;BioMarin and Grace shall share equally in any upfront or other fees paid by BioMarin's
sublicensee(s) in respect of the sublicense(s); provided, however, that earned or running royalties paid
by BioMarin&#146;s sublicensee(s) based on sales of Licensed Product to third
parties shall not be subject to the sharing provisions of this subparagraph. </FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.03
&nbsp;&nbsp;Related Technology used or useful in connection with BioMarin&#146;s activities
pursuant to this Agreement has previously been provided to BioMarin by Grace.
Grace has previously supplied BioMarin, at no additional cost to BioMarin, with
viable cultures of microorganisms capable of producing Vibriolysin. Grace has
previously provided BioMarin, at no additional cost to BioMarin, with copies of
all Grace patents within the Patent Rights. Grace is required to provide any
additional Related Technology (as detailed in the Option Agreement) that might
become known to Grace, but shall have no obligation to conduct any research with
respect to the subject matter of the Patent Rights and Related Technology. </FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.04
&nbsp;&nbsp;BioMarin shall keep books of record sufficient to verify BioMarin&#146;s
compliance with the license provisions of this Article and to verify the
accuracy and completeness of the accounting under Article III, and shall cause
all its sublicensees to do the same. Such books of record shall be preserved for
a period not less than six years after their creation. BioMarin agrees to take
all reasonably necessary steps to make these books of record available for
inspection and copying by Grace, or Grace&#146;s designated representative, at
Grace&#146;s sole expense, upon reasonable notice and during normal business
hours but not more than once during any twelve (12) month period during the term
of this Agreement. </FONT></P>

<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>ARTICLE III
- LICENSE MAINTENANCE FEES &amp; ROYALTIES</FONT></H1>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.01
&nbsp;&nbsp;<U>License Maintenance Fees</U> - As partial consideration for the license
rights granted herein, BioMarin shall pay an annual License Maintenance Fee of
XXXX. The first License Maintenance Fee shall be due ten (10) days following the
date of signature of the last Party to execute this Agreement. Subsequent annual
License Maintenance Fee payments shall be due on the anniversaries of the
Effective Date. </FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.02
&nbsp;&nbsp;<U>Minimum Annual Royalty</U> - A Minimum Annual Royalty payment of XXXX. The
Minimum Annual Royalty paid for each Contract Year shall be applied as a credit
against Earned Royalties payable in that Contract Year. There shall be no refund
of any Minimum Annual Royalty and there shall be no carryover of Minimum Annual
Royalty to any subsequent Contract Year. </FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.03
&nbsp;&nbsp;<U>Earned Royalty</U> - Subject to application of the royalty credit of
Paragraph 3.02, an Earned Royalty shall be payable by BioMarin to Grace based on
the cumulative Annual Net Sales (&#147;ANS&#148;) of Licensed Products for each
Contract Year, based on the following rate schedule:</FONT></p>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Annual Net Sales ("ANS")&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Royalty</U></font></p>
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Through XXXXXXX&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;XXX of ANS</font></p>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Over XXXXXXX,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;XXX of ANS XXXX<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;through XXXXXXX&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;through XXXXX</font></p>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Over XXXXX&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;XXX of ANS over XXXXX</font></p>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>For example, if the cumulative ANS for a Contract Year is XXXXXX, the total Earned Royalty payable to Grace for that
Contract Year would be:</font></P>

<p><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;XXXXXX + XXXXXX + XXXXXX = XXXXXX.</font></p>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.04&nbsp;&nbsp;Earned Royalties shall be calculated and payable XXXXXXX.  Subject to application of the royalty
credit for Minimum Annual Royalty payments pursuant to Paragraph 3.02, payment of the amount of the calculated
Earned Royalties shall be paid to Grace within sixty (60) days following the end of each calendar quarter.
Notwithstanding the foregoing, in the event of any intellectual property claim, cause of action or litigation
asserted against BioMarin as a result of its practice of the Patent Rights or Related Technology, BioMarin shall
have the right to withhold XXXXXX of the Earned Royalties otherwise payable hereunder and to apply such withheld
amounts against the costs and expenses incurred by BioMarin in connection with such claim, cause of action or
litigation, until such time as the claim, cause of action or litigation has been fully and finally resolved,
following which full payment of Earned Royalties would resume.</FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.05&nbsp;&nbsp;A full accounting of the calculation of the Earned Royalties by BioMarin, including the country in
which each Licensed Product was sold by or on behalf of BioMarin or its sublicensee(s), shall accompany each royalty
payment, and such an accounting shall be delivered to Grace even if no Earned Royalties are payable for that quarter.</FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.06&nbsp;&nbsp;All royalties due Grace by BioMarin under this Agreement (either minimum annual or earned
royalties) shall be payable in U.S. dollars, with the rate of exchange for any non-U.S. currencies received for any
sales being the exchange rate specified in the American edition of the Wall Street Journal.  U.S.-dollar equivalence
shall be calculated on a quarterly basis, using the average of the exchange rate on the first and last business day
of the quarter for each of the currencies in which sales of Licensed Product(s) were made during the quarter.</FONT></P>


<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>ARTICLE IV - CONFIDENTIALITY</Font></h1>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.01&nbsp;&nbsp;During the Term of this Agreement and for a period of two (2) years thereafter, BioMarin and Grace
each shall use their best efforts to protect the confidentiality of proprietary information provided to it by the
other Party and identified in writing or orally as confidential and proprietary and shall not use such information
except for the purposes of this Agreement.  This obligation of confidentiality shall not apply to information which:</FONT></P>
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;is or becomes known publicly through no fault of the receiving Party;</FONT></P>
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;is obtained by the receiving Party from a third party entitled to disclose it;</FONT></P>
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;is already known to the receiving Party at the time of disclosure under this Agreement or
                  under previous agreements between the Parties, including the Option Agreement; or</FONT></P>
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;is developed by the receiving Party independent of any disclosure made hereunder or under
                  previous agreements between the Parties, including the Option Agreement, which can be demonstrated
                  by written or other documentary evidence.</FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.02&nbsp;&nbsp;The confidentiality obligations of this Article IV do not apply when such disclosure of
information is required by law.  Nothing in the confidentiality obligations of this Article IV shall be construed to
prevent BioMarin from any sale or use of any Licensed Product.</FONT></P>


<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>ARTICLE V - REPRESENTATIONS, WARRANTIES, AND INDEMNIFICATION</font></h1>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.01&nbsp;&nbsp;Grace represents and warrants that:</FONT></P>
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;Grace owns all rights, title and interest in and to the Patent Rights and Related Technology;</FONT></P>
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;As of the date of the Option Agreement (May 1, 1998), Grace was not aware of any patent or other
intellectual property rights of third parties which would be infringed by practice of the Patent Rights or Related
Technology;</FONT></P>
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;Grace has the right to enter into this Agreement, to fully comply with the terms and conditions of
this Agreement and to grant to BioMarin the rights and licenses granted herein; and</FONT></P>
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;Grace has not executed any agreement or contract that is inconsistent with the rights and licenses
granted hereunder.</FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.02&nbsp;&nbsp;BioMarin represents and warrants that:</FONT></P>
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;BioMarin has the right to enter into this Agreement and to fully comply with the terms and
conditions of this Agreement;</FONT></P>
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;BioMarin shall use its best efforts to commence clinical testing of Licensed Products after the
Effective Date of this Agreement; and</FONT></P>
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)      BioMarin shall use its best efforts to obtain regulatory clearance for and to commercialize
Licensed Product.</FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.03&nbsp;&nbsp;Nothing in this Agreement shall be read or construed as:</FONT></P>
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;a warranty or representation as to the commercial utility of the Licensed Product or any product
based on the Patent Rights or Related Technology;</FONT></P>
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;a warranty or representation that any pending application within the Patent Rights will mature
into an issued patent;</FONT></P>
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp; a warranty or representation as to the validity or scope of any Patent Rights; or</FONT></P>
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;a warranty or representation that anything made, used, or otherwise disposed of under this
Agreement is or will be free from infringement of patents, copyrights or trademarks of third parties; or</FONT></P>
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;&nbsp;an obligation on the part of Grace to bring or prosecute actions or suits against third parties
for infringement.</FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.04&nbsp;&nbsp;As between Grace and BioMarin, BioMarin shall have sole control and responsibility for the
manufacture, use and/or sale of Licensed Products.  BioMarin shall bear the full responsibility for any liability to
any customers and others for any Licensed Product made by or on behalf of BioMarin or any BioMarin sublicensee or
any BioMarin distributor, and shall indemnify and hold Grace and its corporate Affiliates harmless from any
judgment, claim, expense or liability arising out of the sale of Licensed Product(s) by or on behalf of BioMarin
and/or any BioMarin sublicensee and/or any BioMarin distributor (including direct, consequential and punitive
damages).</FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.05&nbsp;&nbsp;BioMarin further warrants that any manufacture, use and/or sale of Licensed Product(s) by or on
behalf of BioMarin or any BioMarin sublicensee shall be in substantial compliance with all material laws,
regulations, and necessary governmental permits and approvals that are applicable.</FONT></P>


<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>ARTICLE VI - PATENT PROSECUTION &amp; MAINTENANCE</FONT></H1>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.01&nbsp;&nbsp;Grace shall use reasonable efforts to prosecute, as Grace sees fit, the pending patent
applications within the Patent Rights, using counsel selected by Grace and with due consultation with BioMarin.
Grace shall provide BioMarin with copies of all relevant documentation so that BioMarin may be informed and apprised
of the continuing prosecution; BioMarin agrees to keep this documentation confidential.  Grace shall use reasonable
efforts, with due consideration to the stage of prosecution, to amend any patent application within the Patent
Rights to include claims requested by BioMarin to protect the products contemplated by BioMarin to be sold hereunder.</FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.02&nbsp;&nbsp;Grace agrees that no patent or pending patent application within the Patent Rights will be allowed
to lapse or go abandoned without first offering such case(s) to BioMarin.</FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.03&nbsp;&nbsp;BioMarin shall be responsible for all out-of-pocket costs and expenses in connection with the
prosecution and maintenance of the Patent Rights following the Effective Date.  Grace shall submit to BioMarin
itemized invoices for such costs on a quarterly basis and BioMarin shall reimburse Grace for such expenses within
sixty (60) days.  BioMarin will have the right to request and receive from Grace an annual budget for patent
prosecution and maintenance.  BioMarin will have the right to review and negotiate this budget within the standard
of reasonable pharmaceutical industry practice.  This annual budget will not be exceeded by greater than five
percent (5%) without prior consultation with and agreement of BioMarin.</FONT></P>


<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>ARTICLE VII - PATENT ENFORCEMENT AND THIRD PARTY PATENTS</FONT></H1>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.01&nbsp;&nbsp;Grace intends to protect its interests in any Grace patents from infringement by third parties and
to prosecute infringers or otherwise act to eliminate infringement when, in the sole judgement of Grace, such action
is necessary, proper and justified.</FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.02&nbsp;&nbsp;In the event BioMarin believes there is substantial infringement of any patent in the Patent
Rights, which alleged infringement is to the material detriment of BioMarin, BioMarin shall notify Grace and supply
such evidence as it has of the alleged infringement.  Grace shall have the sole right and discretion with respect to
preventing and/or causing the discontinuance of any infringement of Grace patents.  BioMarin agrees that it will, at
Grace's request and expense, furnish such reasonable assistance as may be required to assist in preventing or
discontinuing any such infringement. In the event that Grace fails or refuses, within one hundred twenty (120) days
after notice of any alleged infringement of the Patent Rights, to initiate proceedings to prevent and/or to take
action to cause the discontinuance of such alleged infringement, BioMarin upon notice to Grace may at its option
undertake any such legal proceedings at its own cost and expense, and BioMarin shall be solely entitled to all
recoveries from such litigation.  In any legal proceedings brought by BioMarin pursuant to this Paragraph, BioMarin
agrees to keep Grace advised and informed, and Grace may be represented by counsel of its choice, at Grace's sole
expense, acting in an advisory capacity.  BioMarin may not enter into any settlement agreement adversely affecting
the validity or enforceability of any of the Patent Rights without the express prior written approval of Grace.</FONT></P>


<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>ARTICLE VIII - TERM AND TERMINATION</FONT></H1>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.01&nbsp;&nbsp;This Agreement shall become effective as of the Effective Date.  Unless earlier terminated, the
Agreement shall remain in full force and effect until the last to expire of the patents within the Patent Rights.</FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.02&nbsp;&nbsp;Grace shall have the right to terminate this Agreement only in the event of material breach or
default by BioMarin.  It is understood and agreed that any breach or default in connection with the obligation to
pay fees or royalties hereunder shall be deemed material.  Termination under this Paragraph shall be automatically
effective if such breach or default has not been cured (a) within thirty (30) calendar days after written notice of
the breach to BioMarin if the claimed breach is a failure to pay any amount due and owing hereunder, or (b) within
ninety (90) calendar days after written notice of the breach to BioMarin if the claimed breach is any other material
default hereunder.  Termination under this Paragraph shall automatically terminate any and all sublicenses granted
hereunder by BioMarin.</FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.03&nbsp;&nbsp;BioMarin shall have the right to terminate its license rights under this Agreement for any or no
reason (<u>i.e.</u>, arbitrarily), effective upon ninety (90) days notice in writing to Grace.  BioMarin may so terminate
with respect to the entire Agreement or with respect to one or more patent applications within the Patent Rights;
provided, however, that in the latter case, there shall be no change in the royalty obligations under Article III.
Termination of the entire Agreement under this Paragraph shall automatically terminate any and all sublicenses
granted hereunder by BioMarin.  Termination with respect to one or more patent applications within the Patent Rights
shall automatically result in a similar termination of any and all sublicenses granted hereunder by BioMarin with
respect to such patent application(s).</FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.04&nbsp;&nbsp;For any quantity of Licensed Product which BioMarin or a BioMarin sublicensee has in its
possession or is in the process of manufacturing at the time termination is effective under Paragraph 8.02 or 8.03,
BioMarin may elect to have that quantity of the Licensed Product be subject to the terms of the license as if the
Agreement had not been terminated and may sell or transfer such Licensed Product to third parties for a period of up
to six (6) months, or may elect to have it destroyed or the manufacture thereof canceled.</FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.05&nbsp;&nbsp;At Grace's option, BioMarin shall, upon termination of this Agreement, either return to Grace all
confidential information received pursuant to this Agreement or the Option Agreement, or certify that such
information has been destroyed.  At BioMarin's option, Grace shall, upon termination of this Agreement, either
return to BioMarin all confidential information received pursuant to this agreement or the Option Agreement, or
certify that such information has been destroyed.  Notwithstanding the preceding, each Party would be permitted to
retain one copy of the confidential information, solely for record purposes.</FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.06&nbsp;&nbsp;Expiration or termination of this Agreement shall not discharge, affect or modify any rights or
obligations which accrue or are incurred prior to the date of expiration or termination.  For example, there shall
be no refund or credit of any fees or royalties paid or accrued prior to the date expiration or termination is
effective.</FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.07&nbsp;&nbsp;Sections 2.04, 3.03 (to the extent provided in Paragraph 8.04), 3.04, 3.05, 3.06, and 4.2, and
Articles I, IV, and VIII to X shall survive any expiration or termination of this Agreement.</FONT></P>


<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>ARTICLE IX - ASSIGNABILITY</FONT></H1>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.01&nbsp;&nbsp;Neither this Agreement nor the rights and obligations of either Party hereunder shall be assigned
without the prior written consent of the other Party; provided, however, that such consent will not be unreasonably
withheld for companies within the biopharmaceutical or healthcare industries that are equal to or exceed the
commercial capabilities and financial resources of BioMarin at the time of execution of this Agreement.
Notwithstanding the foregoing, either Party may freely assign this Agreement to any affiliate or to a successor of
the entire business to which this Agreement relates.</FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.02&nbsp;&nbsp;All of the terms, covenants, representations, warranties and conditions of this Agreement shall be
binding upon, and inure to the benefit of and be enforceable by, the Parties hereto and their respective successors.</FONT></P>


<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>ARTICLE X - MISCELLANEOUS</FONT></H1>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.01&nbsp;&nbsp;This Agreement shall be construed and interpreted, and the rights and obligations of the Parties
shall be determined, in accordance with the laws of the State of California, without regard to the conflicts of laws
principles thereof.</font></p>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.02&nbsp;&nbsp;<u>Dispute resolution</u> - In the event of any controversy or claim arising out of or relating to any
provisions of this Agreement or the breach thereof, the Parties shall try to settle those conflicts amicably between
themselves.  Should they fail to agree, the matter in dispute shall be settled through arbitration conducted by and
in accordance with the rules of the American Arbitration Association ("AAA"), except as modified by this Paragraph
10.02.   Either Party may furnish the other Party with a dated, written notice (the "Arbitration Notice") indicating
(i) intent to commence arbitration proceedings, (ii) the nature, with reasonable detail, of the dispute, and (iii)
the remedy sought.  Each arbitration shall be conducted by three arbitrators experienced in pharmaceutical
licensing, consisting of one arbitrator chosen by each Party and the third arbitrator chosen by the first two.  In
the event that the first two arbitrators are not able to agree upon and chose a third arbitrator, the third
arbitrator shall be appointed in accordance with the AAA rules.  The arbitration decision shall be binding and not
appealable to any court in any jurisdiction.  The prevailing Party may enter the arbitration decision in any court
having competent jurisdiction.</font></p>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.03&nbsp;&nbsp;No alteration or amendment of this Agreement shall be effective unless embodied in writing and
executed by an authorized representative of each Party.</FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.04&nbsp;&nbsp;<u>Export Laws</u> - BioMarin agrees to abide by any restrictions or conditions respecting the export or
re-export of Grace information disclosed in connection with this Agreement which is subject to export control under
the Export Administration Regulations of the United States Department of Commerce, or export control regulations of
other United States Government agencies including the Department of State and Department of Treasury.  BioMarin
agrees that it will not export such information, or the direct product thereof, directly or indirectly, to any
countries to which such export is now or hereafter becomes illegal under any such regulations.  Any breach of the
terms of this paragraph by BioMarin shall constitute a material breach, entitling Grace to terminate pursuant to
Paragraph 8.02.  BioMarin further agrees to require all BioMarin sublicensees to abide by the provisions of this
Paragraph.</FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.05&nbsp;&nbsp;<u>Notices</u> - All notices required to be given under this Agreement, and the payment of required fees
and royalties, shall be made by first class air mail or express courier addressed to the respective Party at the
address below, or by telefax to the numbers listed below (for notices), or to such changed address or telefax number
as a Party may designate in writing to the other Party.  Such notice, if received, shall be deemed to have been
received, if by first class mail, on the fifteen (15th) calendar day after posting; if by express courier, on the
date of delivery by the courier; and if by telefax, upon transmission with electronic confirmation of receipt.</FONT></P>
<pre>
        If to Grace:    Attn:   Dr. Nils Friis
                        W.R. Grace &amp; Co.
                        5400 Broken Sound Boulevard NW, Suite 300
                        Boca Raton FL  33487-2702

                        Telefax #:  (561) 362-1323

        with a copy to: Attn:  Chief Patent Counsel
                        W.R. Grace &amp; Co.
                        7500 Grace Drive
                        Columbia MD  21044

                        Telefax #:  (410) 531-4195

        If to BioMarin: Attn:  William Anderson, Cheif Operating and Financial Officer
                        BioMarin Pharmaceutical Inc., Suite 210
                        371 Bel Marin Keys Boulevard, Suite 210
                        Novato, CA  94949

                        Telefax #:  (415) 382-7889
</pre>
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.06&nbsp;&nbsp;<u>Force Majeure</U> - Each Party shall be excused from the performance of its obligations hereunder in
the event that such performance is prevented by force majeure, provided that each Party so affected shall use
commercially reasonable efforts to alleviate the force majeure condition or to complete such performance by other
means.  For the purpose of this Agreement, force majeure is defined as an event beyond the control of the Parties
and independent from their will, including (but not limited to) strikes or other labor trouble, war, insurrection,
fire, flood, explosion, discontinuity in the supply of power or other critical components, court order or
governmental interference and acts of God.</FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.07&nbsp;&nbsp;The Parties to this Agreement are independent contractors and not joint venturers or partners, and
no agency, partnership, or power to obligate the other Party is created by this Agreement.</FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.08&nbsp;&nbsp;If any of the provisions of this Agreement are or become in conflict with the laws or regulations
of any jurisdiction or any governmental entity having jurisdiction over the Parties or the subject matter, those
provisions shall be deleted and the remaining terms and conditions of this Agreement shall remain in full force and
effect.</FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.09&nbsp;&nbsp;This Agreement constitutes the entire understanding of the Parties with respect to the subject
matter hereof and supersedes and previous understandings and agreements, written or oral, which between the Parties
hereto may have reached with respect to the subject matter, including the Option Agreement.</FONT></P>

<b>IN WITNESS WHEREOF</b>, the Parties hereto have duly executed this Agreement in duplicate originals.
<pre>
BIOMARIN PHARMACEUTICAL INC.

By:    /s/ Raymond W. Anderson
       ------------------------------------
Name:  Raymond W. Anderson
Title: Chief Financial and Operating Officer
Date:  March 28, 2001


W. R. GRACE &amp; CO.

By:    /s/ Kevin Coghlan
       -------------------------------------
Name:  Kevin Coghlan
Title: Vice President, Business Development
Date: March 26, 2001

</pre>
Attachments:      Appendix A - Patent Rights
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
